EZH2 and lymphoma: The transcriptomic analysis of 347 DLBCL patient samples by Enishi et al. demonstrated that EZH2 mutation enrichment of MHC class I and II negative lymphomas was associated with a reduced T cell infiltrate in subsequent studies in vivo, which was reversed by EZH2 inhibition [12•].